

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1647
RECEIVED
JAN 16 2001
TECH CENTER 1600/2900

In the Application of:

Barbara K. Fack

Serial No. 09/373,828

Filed: August 13, 1999

Title: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT
OF PSORIASIS AND PSORIATIC ARTHRITIS

Docket No. 2945

Group Art Unit: 1647

Examiner D. Romeo

Date: January 8, 2001

Assistant Commissioner for Patents
BOX NON-FEE
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT AND
PRELIMINARY AMENDMENT

Please enter the following amendments into the above-described patent
application:

In the Claims:

Please add the following new claim:

--23. The method of Claim 7, wherein the concurrently administered
medication is celecoxib.--

REMARKS

Response to Restriction Requirement and Election of Species:

In response to the Restriction Requirement mailed December 13, 2000, the Applicant hereby elects Group I for immediate prosecution. This group includes Claims 1-13, which pertain to the treatment of psoriatic arthritis with TNFR:Fc. The Applicant reserves the right to pursue Claims 14-22 in a separate patent application.

The examiner has identified Claims 7-10 and 20 as being generic and has stated that these claims and the specification at pages 9-10 refer to several different patentably distinct species of adjunct drug. He has instructed the Applicant to elect a single disclosed species to which the claims will be restricted if no generic claim is found to be allowable. Of these, only Claims 7-10 have been elected for immediate prosecution. In response to the species election requirement, the Applicant elects the